Astellas presents ASP1941 picky SGLT2 inhibitor Taper off 2 cram results at 70th ADA
Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, "Astellas") announced that the ensemble presented results from a Japanese Insert 2 examination conducted with ASP1941, a discriminating SGLT2 inhibitor, at the 70th Well-ordered Sessions of the American Diabetes Friendship (ADA) on June 26, 2010 (EST). ASP1941 is designed to congest the re-absorption of glucose in the kidney and excrete glucose in the urine. The spoken introduction, along with the four announcement presentations, on non-clinical pharmacology, clinical pharmacokinetics/pharmacodynamics and a U.S. Development 2a scrutinize, marks Astellas’ from the word go demeanour at the ADA convergence and demonstrates the company’s commitment to upon treatments quest of diabetes.
During the awarding (75-OR), entitled "ASP1941, a Story, Discriminatory SGLT2 Inhibitor, Was Impressive and Bona fide in Japanese Hale and hearty Volunteers and Patients with Prototype 2 Diabetes Mellitus," Dr. Atsunori Kashiwagi from Shiga University of Medical Information presented evidence from a 12-week dispense find muse about (12.5, 25, 50, 100 mg and placebo) in 361 Japanese patients with Archetype 2 diabetes mellitus. This on showed portion kindred and statistically critical decreases in HbA1c compared to baseline and against placebo of up to 1.3% reaching a apogee at the 50 mg dosage. ASP1941 reduced portion bias dose-dependently and statistically relevant ;mainly up to 2 kg in the 100 mg platoon after 12 weeks. All dosages were understandably tolerated. Based on the results of this dose-finding contemplate, 50 mg has been selected as the dispense recompense the evolving End 3 program in Japan.
PROVENIENCE Astellas Pharma Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
